Microbial translocation has been implicated in the pathogenesis of liver fibrosis and cirrhosis. We sought to determme whether markers of microbial translocation are associated with liver disease progression during coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV),
produce a matrix rich in type 1 collagen, leading to hepatic fibrosis [9] , How important these mechanisms are in HIV/HCV-associated liver disease is unclear.
Events early in HIV infection result in translocation of microbes and microbial products across the gut mucosa into the systemic circulation. The destruction of gut-associated lymphoid tissue occurs early in HIV infection through virus-induced apoptosis of CD4* T lymphocytes of the intestinal submucosa [10] [11] [12] and increases the permeability of the gut. There are limited data on the influence of microbial translocation on HIV/HCV-associated liver disease progression during HIV infection. Balagopal et al, in a cross-sectional study of HIV/HCV-coinfected persons, demonstrated that low CD4^ T-ceU counts and high LPS levels were independently associated with cirrhosis [13] . In a look-back study of 53 HIV-infected individuals with hepatitis C, elevated LPS levels were seen <1 year but not >1 year before cirrhosis diagnosis [13] .
We sought to add to the understanding of the influence of microbial translocation on HIV/HCV-associated liver disease by comparing longitudinal plasma markers of microbial translocation, macrophage activation, and inflammation in HIV/ HCV-coinfected women who experienced significant liver disease progression to markers in women who experienced minimal or no progression. the age is expressed in years, the AST and alanine transaminase (ALT) levels are expressed in units/liter, and the platelet count is expressed as the number of platelets/liter multiplied by 10^ [16] [17] [18] [19] . Liver-associated death was ascertained by review of death certificate. In the case of liver-associated death, the soluble markers were measured on a specimen obtained approximately 1 year before death to ensure that liver disease was present but to avoid measurement of markers that may reflect premortem infectious or inflammatory conditions. 
METHODS

This study involved women from the
Laboratory Methods
Plasma LPS levels were quantified in dupUcate by dUution of plasma specimens to 10% with endotoxin-free water, using a Limulus amebocyte assay (Lonza Group, Switzerland). The background level was subtracted, and LPS levels were calculated by foUowing the manufacturer's recommended protocol. Crude associations between progression and each plasma marker were also assessed at Tl, T2, T3, and aU visits, using t tests. Multiple generalized linear regression models (using Proc GLM) were fit to assess associations and slopes for each serum marker, stratifying by progression status and time and controlling for log HIV RNA level and CD4'' T-cell count. P-values from regression models are reported for demonstrating differences in slopes between progressors and nonprogressors for each plasma marker. AU analyses were performed in SAS software, version 9.2 (SAS Institute, Gary, NC). Graphs were produced using STATA, version 10.0.
RESULTS
Forty-four participants in the Chicago WIHS site were studied, of whom 21 did and 23 did not experience progression of liver disease. Characteristics of the 44 women are in Table 1 . The median interval between Tl and T3 was 4.9 years and did not differ between progressors (4.8 years) and nonprogressors (5.0 years). The majority of women in both groups were African American, and the mean age at Tl was 41.6 years. The CD4* T-ceU count was relatively preserved, with mean values at Tl of 421 cells/mm^ for progressors and 526 ceUs/mm"^ for nonprogressors (P = .27); progressors had a significantly lower mean CD4"^ T-ceU count than nonprogressors on the basis of values from the entire study period (371 vs 492 ceUs/mm^; P = .02). and P = .002, respectively). Adding alcohol use to the model attenuated the association, but it remained significant (P=.01).
Relationship of Plasma Markers to Liver Disease Progression
Progressors had a higher level of IL-6 overaU than nonprogressors (P = .02), and the level increased significantly over time for progressors (slope, 1.1; P= .03). In the models that adjusted for HIV RNA load and CD4* T-ceU count, the association between progression and IL-6 level remained significant (P = .04 and P = .04, respectively), but when alcohol was added to the model, the association attenuated to nonsignificance (P= .10). 
Relationship of Plasma Markers to CQH* T-Cell Count
with a higher CD4* T-cell count {P = ,001). There was no signif-A higher IL-6 level was associated with a lower CD4"^ T-cell icant relationship between CD4"^ T-cell count and levels of LPS count (P = ,02), and a higher EndoCAb level were associated (P = ,63), sCD14 (P = ,34), IL-10 P = (,82), or TNF-a (P = .60), ' By the ttest.
Adjusted for log human immunodeficiency virus RNA load.
° One subject did not have data for 1 visit.
DISCUSSION
In this study, we demonstrated that levels of markers of macro- found that, while the LPS level was higher in patients with viral hepatitis, the level did not correlate with liver disease severity.
However, the sCD14 level was associated with cirrhosis and markers of hepatic inflammation. As in our study, the downstream effects of microbial translocation, monocyte activation, and IL-6 secretion were associated with liver disease progression, but the LPS level itself was not. Of interest, Sandler et al found that a higher sCD14 level predicted nonresponse to hepatitis C therapy [25] . 
